Understanding how T cell receptors recognize different peptides
Official title: Revealing the Structural Determinants of TCR Cross-Recognition via Extended Positional Scanning
Funded at University of Notre Dame · NIH-11165449 · Data updated 2026-11-12
This study is looking at how T cells, which are important for fighting diseases like cancer and autoimmune disorders, recognize different pieces of proteins, and it aims to make T cell treatments safer and more effective for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $76,984 |
| NIH project number | 1F32AI191525-01 |
| Project ID | NIH-11165449 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients with conditions that could benefit from T cell therapies, such as cancer, viral infections, or autoimmune disorders.
✕Less likely to help
Patients who do not have conditions amenable to T cell therapy may not receive any benefit from this research.
What this research studies
This research investigates how T cell receptors (TCRs) interact with various peptide antigens presented by major histocompatibility complex (MHC) proteins. By analyzing the structural determinants that influence TCR cross-recognition, the study aims to improve the safety and efficacy of T cell therapies for conditions like cancer and autoimmune diseases. The approach involves advanced techniques to predict TCR behavior and assess the range of peptides they can respond to, which is crucial for developing targeted therapies. Patients may benefit from more precise and safer T cell therapies as a result of this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective T cell therapies for various diseases.
How similar studies have gone: Previous research has shown promise in improving T cell therapies, but this approach aims to address specific limitations in current predictive methods, making it a novel endeavor.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Brambley, Chad — University of Notre Dame
- Study coordinator: Brambley, Chad
Related research
Other NIH-funded projects on the same topics.
-
Designer covalent blockers to stop IgE-driven allergic reactions
A new approach aims to block IgE antibodies that trigger allergic reactions in people with allergic asthma, potentially reducing severe symptoms without broad immune suppression.
-
A life-course view of how early adversity shapes health as people grow up
This NIH grant looks at how tough experiences in childhood and adolescence affect health and aging later in life, using data from people and animal studies to understand why some outcomes are worse and how social factors can help.
-
How a simple, evidence-based approach helps mothers and kids in Peru feel better
A study tests a flexible, lay-delivered mental-health program called CETA for mothers of young children in Lima to improve family well-being.
-
Open-Source tools to test conversational AI for dementia care
A multilingual AI benchmarking project aims to help improve chatbots and virtual assistants used in Alzheimer’s and related dementias, with open tools and datasets for researchers and clinicians.
-
Decoding how human CD8+ T cells recognize donor HLA in transplant rejection
This project studies why certain T cells attack transplanted kidneys, with the goal of understanding which cells drive acute rejection and how they recognize donor HLA.
-
Targeted antibody-guided nanoparticles to treat CMV infection
A new treatment approach combines CMV-targeting antibodies with drug-loaded nanoparticles to deliver antiviral medicine directly to infected cells, aiming to improve efficacy and reduce side effects for people with CMV infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.